ADAGIO THERAPEUTICS, INC.

(ADGI)
  Report
Real-time Estimate Cboe BZX  -  01:06 2022-08-16 pm EDT
3.785 USD   -5.14%
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlights - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mithril Capital Management LLC Solicits Proxies from Shareholders of Adagio Therapeutics Inc

06/06/2022 | 06:08am EDT

On June 6, 2022, Mithril Capital Management LLC announced that it has filed a definitive proxy statement with SEC and urged the shareholders of Adagio Therapeutics Inc to vote for its board nominees Tamsin Berry, Marc Elia and Clive A. Meanwell, and declassification proposal, at the annual meeting of shareholders scheduled to be held on June 22, 2022.


© S&P Capital IQ 2022
All news about ADAGIO THERAPEUTICS, INC.
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
08/15Adagio Therapeutics Q2 Net Loss Narrows
MT
08/15Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highligh..
GL
07/05ADAGIO THERAPEUTICS : Announces Results of Annual Meeting of Stockholders and Evolution of..
PU
07/05ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
07/05SECTOR UPDATE : Health Care Stocks Struggle Tuesday
MT
07/05SECTOR UPDATE : Health Care Stocks Retreating in Tuesday Trade
MT
07/05SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on ADAGIO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -271 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 434 M 434 M -
EV / Sales 2022 -
EV / Sales 2023 16,9x
Nbr of Employees 102
Free-Float 67,2%
Chart ADAGIO THERAPEUTICS, INC.
Duration : Period :
Adagio Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAGIO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 3,99 $
Average target price 3,83 $
Spread / Average Target -3,93%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial & Business Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAGIO THERAPEUTICS, INC.-45.04%434
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-20.33%40 492
BIONTECH SE-36.97%39 486